Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver
Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement
Heliostar Presents Q3 2026 Financial and Operating Results with Record Mine Operating Earnings and Cash Balance
